i-Base home
Search Menu
  • Home
  • HTB
  • 2020
  • March
  • 12

12 March 2020

Contents

Editorial

  • HTB 12 March 2020 now online
  • HTB survey 2020 – please help with feedback

Special reports

  • Fit for purpose: antiretroviral treatment optimisation March 2020
  • HIV pipeline 2020: new drugs in development – March 2020

Conference reports

  • Conference on Retroviruses and Opportunistic Infections (CROI 2020)
  • CROI 2020: Special session on COVID-19
  • Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally
  • Long-acting cabotegravir and rilpivirine injections support two-monthly dosing
  • Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing
  • First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance
  • Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
  • Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women
  • London patient is second person to be cured of HIV from allogeneic stem-cell transplant
  • The London Patient tells his story as second person cured of HIV

Treatment access

  • Dolutegravir/lamivudine FDC recommended by NHS England

PDFs

  • 12 March 2020 vol 21 no 3
  • HTB RSS

Early access

  • US government has altered more than 100 scientific databases since 20 January 5 July 2025
  • All early access reports

Current issues

  • July 2025
  • June 2025
  • May 2025
  • Back issues

Special report

  • Why the new HIV PrEP guidelines from the UK are so exciting (2025) 2 July 2025

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage
  • Donate

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
Registered charity number: 1081905. Company number: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Donate
Feedback
Advice and information
Q and A
Guides
HIV meds
Glossary
Research reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
News and updates
Sitemap
Home
Find us on Facebook
i-Base on Facebook